Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis

Hui-Ling Liang, Shu-Juan Ma, Yan-Ni Xiao, Hong-Zhuan Tan, Hui-Ling Liang, Shu-Juan Ma, Yan-Ni Xiao, Hong-Zhuan Tan

Abstract

Background: The safety and efficacy of different drugs in treatment of gestational diabetes mellitus (GDM) patients who could not maintain normal glucose level only through diet and exercise remains to be debated. We performed this network meta-analysis (NAM) to compare and rank different antidiabetic drugs in glucose level control and pregnancy outcomes in GDM patients.

Methods: We searched PubMed, Cochrane Library, Web of Science, and Embase up to December 31, 2016. Randomized controlled trials (RCTs) related to different drugs in the treatment of GDM patients were enrolled. We extracted the relevant information and assessed the risk of bias with the Cochrane risk of bias tool. We did pair-wise meta-analyses using the fixed-effects model or random-effects model and then adopted random-effects NAM combining both direct and indirect evidence within a Bayesian framework, to calculate the odds ratio (OR) or standardized mean difference (SMD) and to draw a surface under the cumulative ranking curve of the neonatal and maternal outcomes of different treatments in GDM patients.

Results: Thirty-two randomized controlled trials (RCTs) were included in this NAM, including 6 kinds of treatments (metformin, metformin plus insulin, insulin, glyburide, acarbose, and placebo). The results of the NAM showed that regarding the incidence of macrosomia and LGA, metformin had lower incidence than glyburide (OR, 0.5411 and 0.4177). In terms of the incidence of admission to the NICU, insulin had higher incidence compared with glyburide (OR, 1.844). As for the incidence of neonatal hypoglycemia, metformin had lower incidence than insulin and glyburide (OR, 0.6331 and 0.3898), and insulin was lower than glyburide (OR, 0.6236). For mean birth weight, metformin plus insulin was lower than insulin (SMD, -0.5806), glyburide (SMD, -0.7388), and placebo (SMD, -0.6649). Besides, metformin was observed to have lower birth weight than glyburide (SMD, 0.2591). As for weight gain, metformin and metformin plus insulin were lower than insulin (SMD, -0.9166, -1.53). Ranking results showed that glyburide might be the optimum treatment regarding average glucose control, and metformin is the fastest in glucose control for GDM patients; glyburide have the highest incidence of macrosomia, preeclampsia, hyperbilirubinemia, neonatal hypoglycemia, shortest gestational age at delivery, and lowest mean birth weight; metformin (plus insulin when required) have the lowest incidence of macrosomia, PIH, LGA, RDS, low gestational age at delivery, and low birth weight. Besides, insulin had the highest incidence of NICU admission, acarbose had the lowest risk of neonatal hypoglycemia.

Conclusion: Our study concluded that metformin is fastest in glucose control, with a more favorable pregnancy outcomes-would be a better option, but its rate of glucose control is the lowest.However, glyburide is the optimumtreatment regarding the rate of glucose control, but withmore adverse outcomes. This NAMbased on 32 RCTs will strongly help to guide further development of management for GDM patients, clinicians should carefully balance the risk-benefit profile of different treatments according to various situations.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of study selection.
Figure 2
Figure 2
(A–E) The network plot of eligible comparisons for different treatments.
Figure 3
Figure 3
(A–E) The comparison-adjusted funnel plot from network meta-analysis.

References

    1. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 2007;30(suppl 2):S141–6.
    1. Coustan DR. Gestational diabetes mellitus. Clin Chem 2013;59:1310–21.
    1. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(suppl 1):S81–90.
    1. Wikipedia contributors. Gestational diabetes. Wikipedia, The Free Encyclopedia. August 2017.
    1. Coetzee EJ. Pregnancy and diabetes scenario around the world: Africa. Int J Gynaecol 2009;104(suppl 1):S39–41.
    1. Glueck CJ, Goldenberg N, Streicher P, et al. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002;3:1557–68.
    1. Nicholson W, Baptisteroberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol 2011;25:51–63.
    1. Norman RJ, Wang JX, Hague W. Should we continue or stop insulin sensitizing drugs during pregnancy? Curr Opin Obstet Gynecol 2004;16:245–50.
    1. Petry CJ. Gestational diabetes: risk factors and recent advances in its genetics and treatment. Br J Nutr 2010;104:775–87.
    1. Maymone AC, Baillargeon JP, Menard J, et al. Oral hypoglycemic agents for gestational diabetes mellitus? Expert Opin Drug Saf 2011;10:227–38.
    1. Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med 2004;15:51–5.
    1. Collier CA, Bruce CR, Smith AC, et al. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol 2006;291:182–9.
    1. Serrano-Martin X, Payares G, Mendoza-Leon A. Glibenclamide, a blocker of K+ATP channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother 2006;50:4214–6.
    1. Li G, Zhao S, Cui S, et al. Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. Arch Gynecol Obstet 2015;292:111–20.
    1. Zeng YC, Li MJ, Chen Y, et al. The use of glyburide in the management of gestational diabetes mellitus: a meta-analysis. Adv Med Sci 2014;59:95–101.
    1. Silva JC, Pacheco C, Bizato J, et al. Metformin compared with glyburide for the management of gestational diabetes. Int J Gynaecol Obstet 2010;111:37–40.
    1. Kalra B, Gupta Y, Singla R, et al. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. N Am J Med Sci 2015;7:6–12.
    1. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607–17.
    1. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897–900.
    1. Jiang YF, Chen XY, Ding T, et al. Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials. J Clinical Endocrinol Metab 2015;100:2071–80.
    1. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313–24.
    1. Katsanos K, Spiliopoulos S, Karunanithy N, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg 2014;59:1123.e8–33.e8.
    1. Song G-M, Tian X, Zhang L, et al. Immunonutrition support for patients undergoing surgery for gastrointestinal malignancy: preoperative, postoperative, or perioperative? A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Medicine 2015;94:e1225.
    1. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279–301.
    1. Spiegelhalter D, Thomas A, Best N, et al. WinBugs Version 1.4 User Manual. Cambridge, UK: MRC Biostatistics Unit; 2003.
    1. Ades AE, Welton NJ, Caldwell D, et al. Multiparameter evidence synthesis in epidemiology and medical decision-making. J Health Serv Res Policy 2008;13(suppl 3):12–22.
    1. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE 2013;8:e76654.
    1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163–71.
    1. Hague WM, Davoren PM, Oliver J, et al. Contraindications to use of metformin. Metformin may be useful in gestational diabetes. BMJ 2003;326:762.author reply 762.
    1. Moore LE, Briery CM, Clokey D, et al. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med 2007;52:1011–5.
    1. Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003–15.
    1. Ijas H, Vaarasmaki M, Morin-Papunen L, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG 2011;118:880–5.
    1. Niromanesh S, Alavi A, Sharbaf FR, et al. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. Diabetes Res Clin Pract 2012;98:422–9.
    1. Tertti K, Ekblad U, Koskinen P, et al. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab 2013;15:246–51.
    1. Spaulonci CP, Bernardes LS, Trindade TC, et al. Randomized trial of metformin vs insulin in the management of gestational diabetes. Am J Obstet Gynecol 2013;209:34.e1–7.
    1. Mesdaghinia E, Samimi M, Homaei Z, et al. Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial. Int J Prev Med 2013;4:327–33.
    1. Ijas H, Vaarasmaki M, Saarela T, et al. A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. BJOG 2015;122:994–1000.
    1. Ruholamin S, Eshaghian S, Allame Z. Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: a randomized clinical trial. J Res Med Sci 2014;19:970–5.
    1. Wouldes TA, Battin M, Coat S, et al. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed 2016;72: 2015-309602.
    1. Saleh HS, Abdelsalam WA, Mowafy HE, et al. Could metformin manage gestational diabetes mellitus instead of insulin? Int J Reprod Med 2016;2016:3480629.
    1. Ashoush S, El-Said M, Fathi H, et al. Identification of metformin poor responders, requiring supplemental insulin, during randomization of metformin versus insulin for the control of gestational diabetes mellitus. J Obstet Gynaecol Res 2016;42:640–7.
    1. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134–8.
    1. Anjalakshi C, Balaji V, Balaji MS, et al. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract 2007;76:474–5.
    1. Silva JC, Bertini AM, Taborda W, et al. [Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin]. Arq Bras Endocrinol Metabol 2007;51:541–6.
    1. Ogunyemi D, Jesse M, Davidson M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract 2007;13:427–8.
    1. Lain KY, Garabedian MJ, Daftary A, et al. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol 2009;200:501.e1–6.
    1. Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. J Obstet Gynaecol Res 2013;39:1147–52.
    1. Mirzamoradi M, Heidar Z, Faalpoor Z, et al. Comparison of glyburide and insulin in women with gestational diabetes mellitus and associated perinatal outcome: a randomized clinical trial. Acta Med Iran 2015;53:97–103.
    1. Behrashi M, Samimi M, Ghasemi T, et al. Comparison of glibenclamide and insulin on neonatal outcomes in pregnant women with gestational diabetes. Int J Prev Med 2016;7:88.
    1. Moore LE, Clokey D, Rappaport VJ, et al. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol 2010;115:55–9.
    1. Silva JC, Fachin DR, Coral ML, et al. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med 2012;40:225–8.
    1. George A, Mathews JE, Sam D, et al. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide—a randomised controlled trial. Aust N Z J Obstet Gynaecol 2015;55:47–52.
    1. Refuerzo JS, Viteri OA, Hutchinson M, et al. The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial. Am J Obstet Gynecol 2015;212:389.e1–9.
    1. Ainuddin J, Karim N, Hasan AA, et al. Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. Diabetes Res Clin Pract 2015;107:290–9.
    1. Casey BM, Duryea EL, Abbassi-Ghanavati M, et al. Glyburide in women with mild gestational diabetes: a randomized controlled trial. Obstet Gynecol 2015;126:303–9.
    1. Bertini AM, Silva JC, Taborda W, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med 33, 2005, 519–523.
    1. Hassan JA, Karim N, Sheikh Z. Metformin prevents macrosomia and neonatal morbidity in gestational diabetes. Pak J Med Sci 2012;28:384–9.
    1. Mukhopadhyay P, Bag TS, Kyal A, et al. Oral hypoglycemic glibenclamide: can it be a substitute to insulin in the management of gestational diabetes mellitus? A comparative study. J SAFOG 2012;4:28–31.
    1. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism 2013;62:1522–34.
    1. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683–91.
    1. Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS ONE 2013;8:e64585.
    1. Su DF, Wang XY. Metformin vs insulin in the management of gestational diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014;104:353–7.
    1. Balsells M, Garcia-Patterson A, Sola I, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015;350:h102.
    1. Kitwitee P, Limwattananon S, Limwattananon C, et al. Metformin for the treatment of gestational diabetes: an updated meta-analysis. Diabetes Res Clin Pract 2015;109:521–32.
    1. Zhu B, Zhang L, Fan YY, et al. Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. Ir J Med Sci 2016;185:371–81.
    1. Loymans RJ, Gemperli A, Cohen J, et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 2014;348:g3009.
    1. Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol 2002;2:13.
    1. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
    1. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61:455–63.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner